Search

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Phase III EMPA-KIDNEY trial will stop early

The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

She finds purpose in the saddle and pursues a passion for horses – at home and work

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Why role models matter for black veterinarians: One doctor's story

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Diabetes

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Topline results from Boehringer's Phase III IPF Study

Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers